Oruka Therapeutics (NASDAQ:ORKA) Research Coverage Started at TD Cowen

TD Cowen initiated coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report released on Monday, Marketbeat reports. The firm issued a buy rating on the stock.

A number of other analysts also recently issued reports on ORKA. Wedbush started coverage on Oruka Therapeutics in a research report on Wednesday, September 4th. They issued an outperform rating and a $40.00 target price on the stock. Jefferies Financial Group began coverage on Oruka Therapeutics in a research report on Friday, September 13th. They set a buy rating and a $40.00 price target on the stock. Four investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Oruka Therapeutics presently has an average rating of Buy and an average target price of $41.25.

Oruka Therapeutics Price Performance

Oruka Therapeutics stock opened at $24.82 on Monday. Oruka Therapeutics has a 1-year low of $18.72 and a 1-year high of $53.88.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.